22.84

5.76% +1.245

After Hours: 22.845

Jasper Therapeutics Inc (JSPR)

Overview News Price History Option Chain Financials Discussions Forecast

Jasper Therapeutics Inc stock is currently priced at $22.84, with a 24-hour trading volume of 77,712. It has seen a +5.76% increased in the last 24 hours and a -5.48% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $21.34 pivot point. If it approaches the $23.29 resistance level, significant changes may occur.

Previous Close:

$21.60

Open:

$21.77

24h Volume:

77,712

Market Cap:

$344.63M

Revenue:

Net Income/Loss:

$-64.47M

P/E Ratio:

-23.08

EPS:

-0.99

Net Cash Flow:

$-52.33M

1W Performance:

+6.65%

1M Performance:

-5.48%

6M Performance:

+3,633%

1Y Performance:

+1,374%

1D Range:

$21.77

$23.05

52W Range:

$0.40

$31.01

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name

Jasper Therapeutics Inc

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

650 549 1400

Address

2200 Bridge Parkway, Suite 102, Redwood City

Employee

Twitter

Next Earnings Date

2024-06-06

Latest SEC Filings

JSPR's Discussions on Twitter

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-11-23	Initiated	CapitalOne	Overweight
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight
Nov-08-21	Initiated	Credit Suisse	Outperform
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform
Oct-13-21	Initiated	Oppenheimer	Outperform

View All

Jasper Therapeutics Inc Stock (JSPR) Latest News

Jasper Therapeutics, Inc. (NASDAQ:JSPR) to Post Q2 2024 Earnings of ($0.96) Per Share, William Blair Forecasts - MarketBeat

MarketBeat

Jasper Therapeutics, Inc. (NASDAQ:JSPR) to Post Q2 2024 Earnings of ($0.96) Per Share, William Blair Forecasts - Defense World

Defense World

(JSPR) Investment Analysis - Stock Traders Daily

Stock Traders Daily

Equities Analysts Offer Predictions for Jasper Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:JSPR) - Defense World

Defense World

HC Wainwright Reaffirms "Buy" Rating for Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat

MarketBeat

Jasper Therapeutics, Inc. Expected to Post Q1 2025 Earnings of ($0.91) Per Share (NASDAQ:JSPR) - MarketBeat

MarketBeat

Jasper Therapeutics Inc Stock (JSPR) Financials Data

Jasper Therapeutics Inc (JSPR) Net Income 2024

JSPR net income (TTM) was -$64.47 million for the quarter ending December 31, 2023, a -71.06% decrease year-over-year.

Jasper Therapeutics Inc (JSPR) Cash Flow 2024

JSPR recorded a free cash flow (TTM) of -$52.33 million for the quarter ending December 31, 2023, a -12.71% decrease year-over-year.

Jasper Therapeutics Inc (JSPR) Earnings per Share 2024

JSPR earnings per share (TTM) was -$6.1852 for the quarter ending December 31, 2023, a +39.95% growth year-over-year.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.